13 results about "Hepatitis b surface antigen" patented technology

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.

Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and / or purification of HBsAg.

This invention belongs to the field of affinity membrane and bioseparation technology, and provides a cellulose-based affinity membrane for hepatitis B virus (HBV), its preparation method, and its application. The affinity membrane consists of a base membrane and an affinity ligand immobilized on the base membrane. The base membrane is a carboxylated cellulose filter membrane or a carboxylated modified cellulose filter membrane. The affinity ligand is a biomolecule that specifically recognizes HBV surface antigen. The carboxyl groups of the base membrane and the amino groups of the affinity ligand are linked by amide bonds. Unreacted carboxyl groups on the base membrane are blocked by a blocking reagent. The carboxyl content of the base membrane is 400-1000 μmol / g, the pore size is 400-1000 nm, and the porosity is 30%-60%. The application refers to the use of the above-mentioned affinity membrane in the specific clearance of HBV from HBV-positive plasma. This invention can achieve efficient and specific clearance of HBV from plasma, maximally preserving the activity and function of normal plasma components, and improving the feasibility of industrial application.

A combination comprising a tricycle compound and use thereof in the preparation of a medicament for treating HBV. The combination is a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and any one drug in the following groups a-c: a. a hepatitis B surface antigen inhibitor, b. a reverse transcriptase inhibitor, and c. a hepatitis B surface antigen inhibitor and a reverse transcriptase inhibitor.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

The application belongs to the technical field of pharmaceutical chemistry, and discloses a compound for inhibiting hepatitis B surface antigen and application thereof. It is proved through research that the recombinant plasmid S-HiBiT constructed can characterize the expression and secretion of HBs, and can be used for screening the compound for inhibiting HBs, and a cell model for screening anti-HBV drugs targeting HBsAg, i.e. HepG2-PB-S-HiBiT stable expression cell line. It is verified through experiments that the model is particularly suitable for high-throughput screening of compounds. Compound 1 and compound 3 capable of inhibiting HBsAg are found through screening of a compound library by using the model, the drug has the potential to be further developed into a hepatitis B treatment candidate drug, and a new drug is provided for the treatment of hepatitis B.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

There is provided a method of curing chronic hepatitis B infection in a human, the method comprising administering to a subject in need thereof an effective amount of one or both of an exogenous anti-HBs antibody or an anti-HBs antibody producing carrier, the present invention relates to a method for reducing cellular and blood hepatitis B surface antigen (HBsAg) by providing continuously increased levels of anti-HBs antibodies in the subject.

The present application relates to the technical field of immunological detection, in particular to hepatitis B PreS1 antigen and its preparation method and application. The present application first selects an active PreS1 polypeptide sequence, which is coupled to a hepatitis B surface antigen HBsAg molecule through a crosslinking agent to obtain a hepatitis B PreS1 antigen having both hepatitis B surface antigen activity and PreS1 antigen activity, which can be used as a calibrator and positive control in a hepatitis B PreS1 antigen detection kit. The kit uses anti-PreS1 antibody as coating and anti-HBsAg antibody as enzyme label. The artificial coupled hepatitis B PreS1 antigen prepared by the present application can effectively replace the currently used PreS1 real positive sample on the market, has no biological safety risk, stable source, and various indexes such as reactivity, vehicle stability and thermal stability, which are all better than those of the real positive sample, and has high innovation and applicability.

The invention discloses a nano antibody targeting a hepatitis B surface antigen and application of the nano antibody. The nano antibody has an amino acid sequence as shown in SEQ ID NO: 1-5, and has high affinity to HBsAg. The nano antibody not only can effectively neutralize hepatitis B virus, but also can enter cells to realize'multi-link and all-directional 'inhibition of virus life cycle, including inhibition of virus RNA transcription, protein expression, nucleocapsid assembly, DNA replication and particle secretion, and can significantly down-regulate HNF4alpha, Sp1 and other key transcription factors in host hepatocytes. The antibody can be efficiently expressed in a prokaryotic or eukaryotic system. The PEGylated derivative (such as Nb1-PEG40) can prolong the half-life period, and shows stronger effects of clearing serum HBsAg and inhibiting liver virus replication in an HBV infected mouse model. The invention provides a new strategy and drug candidate for hepatitis B treatment.

This invention discloses a non-invasive systemic assessment method and system for predicting the transformation of follicular lymphoma. The method includes the following steps: S1, obtaining four characteristics of the subject: peripheral blood hepatitis B surface antigen (HBsAg), neutrophil-to-lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), and PET-CT reporting maximum standardized uptake (SUVmax); S2, determining the weight of each characteristic based on its importance, with the weights from high to low being HBsAg, LDH, NLR, and SUVmax, and converting each characteristic into a risk score of 0-3 points using a unique fixed node; S3, weighted summing of the scores of the four characteristics to obtain a total score S, establishing a correspondence between the total score and transformation, constructing a web-based calculator and transformation scoring system, and outputting the individual transformation probability prediction result. By embedding the four conventional indicators (HBsAg, NLR, LDH, and SUVmax) selected by LASSO and Boruta into a lightweight CatBoost model, the transformation probability can be output, realizing a non-invasive assessment of the histological transformation risk of follicular lymphoma at initial diagnosis.

The present invention belongs to the field of biopharmaceutics and in particular relates to a pharmaceutical composition. The pharmaceutical composition comprises a hepatitis B surface antigen, a hepatitis B core antigen, and an immunostimulatory composition, wherein the immunostimuilatory composition comprises a saponin and a CpG oligodeoxynucleotide, or consists of an adjuvant comprising a saponin and a CpG oligodeoxynucleotide.

The invention discloses a preparation method of an anti-human hepatitis B surface antigen monoclonal antibody. The preparation method comprises the following steps: step 1, extracting a human hepatitis B surface antigen HBsAg; 2, selecting an experimental animal, wherein the experimental animal is a mouse; 3, animal immunization is conducted on the mouse, purified antigen HBsAg is injected for immunization, and injection positions are subcutaneous and abdominal cavities; step 4, continuing to carry out second immunization and third immunization by using the same dose of antigen and the same method; step 5, using the same dosage of antigen and the same method to carry out booster immunization before cell fusion; 6, taking out the spleen of the mouse after three days of boosted immunization, preparing a cell suspension, preparing myeloma cells, and fusing the cell suspension and the myeloma cells into hybridoma cells; 7, screening hybridoma cells, and culturing and cloning the screened hybridoma cells; and 8, preparing ascites, and purifying the ascites to obtain the monoclonal antibody. Compared with the prior art, the invention has the advantage of providing the preparation method of the anti-human hepatitis B surface antigen monoclonal antibody with higher purity.